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Abstract
A fundamental issue in understanding homeostasis of the hematopoietic system is to what extent intrinsic and extrinsic
factors regulate cell fate. We recently revisited this issue for the case of blood platelets and concluded that platelet life span
is largely regulated by internal factors, in contrast to the long-held view that accumulated damage from the environment
triggers clearance. However, it is known that in humans there is an ongoing fixed requirement for platelets to maintain
hemostasis and prevent bleeding; hence a proportion of platelets may be consumed in such processes before the end of
their natural life span. Whether it is possible to detect this random loss of platelets in normal individuals at steady-state is
unknown. To address this question, we have developed a mathematical model that independently incorporates age-
independent random loss and age-dependent natural senescent clearance. By fitting to population survival curves, we
illustrate the application of the model in quantifying the fixed requirement for platelets to maintain hemostasis in mice, and
discuss the relationship with previous work in humans. Our results suggest a higher requirement for platelets in mice than
in humans, however experimental uncertainty in the data limits our ability to constrain this quantity. We then explored the
relationship between experimental uncertainty and parameter constraint using simulated data. We conclude that in order
to provide useful constraint on the random loss fraction the standard error in the mean of the data must be reduced
substantially, either through improving experimental uncertainty or increasing the number of experimental replicates to
impractical levels. Finally we find that parameter constraint is improved at higher values of the random loss fraction; thus
the model find utility in situations where the random loss fraction is expected to be high, for example during active
bleeding or some types of thrombocytopenia.
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Introduction
The relative contributions of intrinsic versus extrinsic factors in
regulating platelet life span have been the subject of considerable
debate and controversy. A popular explanation first articulated by
Mustard, Roswall and Murphy favoured the extrinsic viewpoint
[1]. Their ‘‘multiple-hit’’ model holds that platelets age by
accumulating damage over time, for example by temporary
involvement in thrombi or via stress, shear or temperature
fluctuations during normal circulation [1,2]. Once a critical level
of damage is reached, the platelet is cleared by the reticuloendo-
thelial system. Studies of size, density and morphology as platelets
age appeared to support this model [3–11]. However, recent
molecular data have challenged this primarily extrinsic view of
platelet ageing. Both platelet count and platelet turnover are
altered in mice with deficiencies in pro- and anti-apoptotic
proteins (in particular Bak and Bcl-xL), indicating an essential role
for the intrinsic apoptosis pathway in platelet homeostasis [12].
We recently attempted to integrate this new molecular
information with the multiple-hit model by fitting the latter to
population and cohort survival curves from mice with mutations in
Bcl-xL and Bak [13]. Although the multiple-hit model generated
adequate fits to the data, the results suggested that it was primarily
the rate of hits rather than the number of hits that differed
between the genotypes – a result that is difficult to reconcile with
the original exposition of the model. Thus, a simpler interpretation
was that, under normal physiological conditions, platelet life span
is not regulated by damage inflicted by extrinsic ‘‘hits’’, but instead
is programmed by an internal timer. We proposed that intrinsic
factors (such as the levels of pro- and anti-apoptotic proteins)
would give rise to a natural distribution of platelet life span.
Although many choices for the mathematical form of this
distribution were possible, we chose the lognormal distribution
as it appeared to provide a simple explanation of the differences
between genotype (i.e. shifting mean log life span). We refer to the
resulting mathematical model as the ‘‘lognormal-senescent’’ or LS
model.
Our conclusion that platelet life span is internally regulated left
open the questions of how the apoptotic program in platelets is
triggered, and what mechanism determines the point at which
each individual platelet enters the apoptotic process. Furthermore,
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e57783
our modelling did not account for the fraction of platelets that are
consumed by normal hemostatic requirements. Hanson et al.
demonstrated a fixed requirement for platelets by studying platelet
survival in patients with varying degrees of bone marrow
hypoplasia [14]. They used a novel approach, first extracting an
estimate of mean life span from the gamma-fit (multiple-hit)
method, and then using the Dornhorst model to correlate mean
life span and platelet count across all patients, assuming an equal
and fixed requirement for platelets in each individual. The
Dornhorst model is a classic model incorporating senescent death
at a fixed time with random loss up until that time. It was
described in 1951 for the study of red cell survival curves [15], but
can in principle be applied to any cell type with these two alternate
cell fates. However, the model suffers from the problem that it
tends to overestimate the random loss fraction when fit directly to
individual survival curves. Hanson et al.’s approach overcame this
problem by not directly relying on fits to survival curves. Rather
they focussed on the predicted reduction in both platelet count and
life span as platelet production was decreased – an approach made
possible by acquiring data from a wide range of patients with
differing degrees of hypoplasia, and controls. They concluded that
approximately 7,000 platelets per microlitre of blood per day are
required to maintain hemostasis, and consequently approximately
18% of platelets in healthy human individuals are consumed
before the end of their natural lifespan.
Here, we address the question of whether it is possible to detect
the fixed requirement for platelets directly from individual survival
curves, i.e. without access to data derived from individuals with
variable platelet production rates. The reason that the Dornhorst
model tends to overestimate the random loss fraction is that it does
not account for the intrinsic variability in cell life span. This
approximation works well for human red cells, whose mean life
span is approximately 120 days with a standard deviation of no
more than 10 days (coefficient of variation (C.V.) ,10%).
However, for wild-type murine platelets the mean life span is
approximately 4 days, with a standard deviation of 1 day (C.V.
,25%). Hence, the curved ‘‘tail’’ of the survival curve tends to
result in a spuriously high estimate of the random loss fraction
when the Dornhorst model is fitted. We therefore developed a
hybrid of the Dornhorst model and the LS model introduced in
our previous study, which we refer to as the Dornhorst-LS or DLS
model. Our results are consistent with a fixed requirement for
platelets to maintain hemostasis, however the biological interpre-
tation of our results is limited by poor constraint of the critical
parameter related to random loss. We quantitatively compare
humans and mice, and note that on face value our results suggest a
fixed requirement for platelets in mice of the order of 100,000 per
microliter of blood per day, much higher than the corresponding
value in humans. We then explore some of the technical difficulties
with our approach that contribute to poor parameter constraint.
Overall, our data and analysis suggest that at steady-state there is a
large excess of platelets and therefore the random loss fraction is
small, and difficult to detect by model fitting to survival curves
alone.
Results and Discussion
Recently, we developed an in vivo double-labeling technique for
studying platelet survival. First, the X488 reagent (Emfret
Analytics, Eibelstadt, Germany) is injected intravenously to label
the majority of platelets in circulation at that particular time, thus
establishing a ‘‘population label’’. X488 is a DyLight488-labeled
rat IgG derivate against the murine GPIbb subunit of the platelet
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the standard technique of in vivo biotinylation is performed [16].
Platelets that are negative for the first label but positive for the
second represent a ‘‘cohort’’ of platelets born in the time period
between the two labelings. Flow cytometric analysis to enumerate
the percentage of platelets carrying combinations of the two labels
yields population and cohort survival curves.
In our previous study we fit two different models, the multiple-
hit model and the LS model, to population and cohort data in
wild-type, Bcl-x+/Plt20 and Bak2/2 mutant mice (for which platelet
life span is shortened or lengthened, respectively). Both models
explain senescent age-dependent platelet death (via different
mechanisms) and appeared to provide adequate fits to the data.
In this study, we address the question of age-independent random
loss (e.g. by consumption in blood clots) and whether its effect on
survival curves can be detected.
As discussed in Materials and Methods, parameter
constraint is an important issue in addressing this question. To
this end, we employed a Monte Carlo technique to estimate
confidence intervals. Briefly, this involves first modelling the
experimental uncertainty about the mean of the data as normally-
distributed (Gaussian) noise. A new, simulated set of survival
curves is then generated with Gaussian noise of the correct
magnitude added about the mean. The model is then refit to this
simulated data and a new set of parameters obtained. This process
is repeated 1000 times, and the empirical distribution of
parameters obtained is used to estimate confidence intervals in
those parameters – indicated by box-and-whisker plots with
outliers (outside of 2.5–97.5 percentiles) plotted individually as dots
in the figures of this paper.
Figure 1. Lognormal-Senescent model fits of platelet survival data. (A) Population survival data and LS model best fits for Bcl-x+/Plt20 (blue),
wild-type (green) and Bak2/2 (red) mice. A Monte Carlo technique was used to generate estimates of confidence intervals for the model parameters –
(B) mean natural life span, m, (C) standard deviation of natural life span, s, (D) random loss rate constant, r (always 0 hr21 for this model), and (E)
random loss fraction, f (always 0 for this model). 1000 Monte Carlo simulations were performed and fit to obtain parameters – box-and-whisker plots
indicate median, interquartile range, 2.5 and 97.5 percentiles, and outliers are plotted as individual dots.
doi:10.1371/journal.pone.0057783.g001
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As well as the intrinsic parameters of the models considered
here (mean life span, standard deviation of life span, and random
loss rate constant) additional parameters are required to fit to the
experimental data. In particular, because the labels are not perfect
(i.e. do not label 100% of platelets) parameters representing the
efficiencies of the two labels, e1 and e2, are required. Furthermore,
as discussed previously [13], the second label – biotin – tends to
continue to label platelets for some period of time after the initial
injection and so another parameter for its half-life is required, b1/2.
These extra parameters are potential confounders in interpreting
our results, so it is best to minimise their impact. To fit the
population survival data requires only one of these additional
parameters, e1, whereas to fit the cohort survival data requires the
other two, e2 and b1/2, as well. Therefore, any advantage that may
be gained by fitting the cohort data must be balanced against the
complication of two additional parameters. We found that fitting
the cohort data did not provide any improvement in the constraint
of the parameters of interest, therefore in the main text we present
results from fitting just the population survival data. In Supple-
mentary Figures and Tables we present the results from
fitting to both the population and cohort survival data, for
reference.
Lognormal-Senescent (LS) model
We began by reproducing the results of our earlier work
[13,17], fitting the LS model using the slightly altered method-
ology described above. Results are illustrated in Figure 1 and best-
fit parameter values and 95% confidence intervals are reported in
Table 1. In Figure 1A, we show what visually appear to be good
Figure 2. Dornhorst model fits of platelet survival data predict that a large proportion of platelets are destroyed randomly. (A)
Population survival data and Dornhorst model best fits for Bcl-x+/Plt20 (blue), wild-type (green) and Bak2/2 (red) mice. A Monte Carlo technique was
used to generate estimates of confidence intervals for the model parameters – (B) natural life span, T, (C) standard deviation of natural life span
(always 0 hr for this model), (D) random loss rate constant, r, and (E) random loss fraction, f. 1000 Monte Carlo simulations were performed and fit to
obtain parameters – box-and-whisker plots indicate median, interquartile range, 2.5 and 97.5 percentiles, and outliers are plotted as individual dots.
doi:10.1371/journal.pone.0057783.g002
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fits to the population survival curves for the three genotypes.
Figures 1B and C show confidence intervals for the mean and
standard deviation parameters, m and s, respectively, from the
Monte Carlo simulation. Figure S1A and B, illustrate the same
information with the alternate parameters –the mean log life span,
m, and the standard deviation of log life span, s – showing that it is
primarily the mean log life span, not the standard deviation in log
life span, that varies between genotypes, in agreement with our
earlier study [13]. Figure 1D and E emphasise that there is no
random loss in this model, and are included simply for comparison
to the Dornhorst and Dornhorst Lognormal-Senescent models in
Figures 2 and 3, respectively.
Dornhorst model
To assess the possibility of age-independent random loss in
addition to the usual age-dependent senescent clearance, we next
fit the classic Dornhorst model [15] to our population survival data
across the three genotypes. The Dornhorst model assumes that
senescent death happens at a definite, fixed age, and that prior to
senescent death cells are destroyed (or consumed) randomly at a
fixed rate. Thus, there are two parameters of the model in its pure
form – the fixed natural life span, T, and the random loss rate
constant, r, as well as the labeling efficiency parameter, e1. The
relative proportion of platelets that are randomly lost or undergo
age-dependent senescent clearance is of interest in discussions of
platelet fate. We refer to the proportion of cells that are randomly
Figure 3. Dornhorst-Lognormal-Senescent model fits of platelet survival data reveals a smaller random loss fraction than the
classic Dornhorst model but wide confidence intervals. (A) Population survival data and DLS model best fits for Bcl-x+/Plt20 (blue), wild-type
(green) and Bak2/2 (red) mice. A Monte Carlo technique was used to generate estimates of confidence intervals for the model parameters – (B)
natural life span, T, (C) standard deviation of natural life span, (D) random loss rate constant, r, and (E) random loss fraction, f. 1000 Monte Carlo
simulations were performed and fit to obtain parameters – box-and-whisker plots indicate median, interquartile range, 2.5 and 97.5 percentiles, and
outliers are plotted as individual dots.
doi:10.1371/journal.pone.0057783.g003
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lost (prior to the end of their natural life span) as the ‘‘random loss
fraction’’, f, throughout this paper. At steady-state in normal
individuals the major source of this random loss of platelets is
envisaged to be hemostatic consumption, and thus the random loss
rate constant and fraction could equally well be referred to as
‘‘consumption rate constant’’ and ‘‘consumption fraction’’.
Equally, in situations where random destruction of platelets is
increased, such as immune thrombocytopenia purpura, ‘‘destruc-
tion’’ may be a more appropriate adjective than ‘‘loss’’. However,
we use the more general term ‘‘random loss’’ throughout our
discussion, to emphasise the more general applicability of the
model. In the Dornhorst model, the random loss fraction is
dependent on the random loss rate constant, r, and the natural life
span, T, via Equation (8) in Materials and Methods.
Figure 2 illustrates Dornhorst model fits to our data, with
confidence intervals on parameter values using the Monte Carlo
technique as described above. Best-fit parameter values and 95%
confidence intervals are shown in Table 2. As expected, the
natural life span is different in the three genotypes (Figure 2B).
More surprisingly, the Dornhorst model predicts very high values
of the random loss rate constant and fraction (Figure 2D and E) –
suggesting of the order of 50% of platelets are randomly lost in
wild-type and Bak2/2 mice (and that this proportion is well-
constrained between approximately 40 and 60%). This is much
higher than previous estimates of this quantity in humans [14].
Figure 2C emphasises that in the Dornhorst model natural death
occurs at a fixed time (the standard deviation in natural death time
is zero). In his original publication, Dornhorst stressed that the
assumption of a fixed age of death is an approximation valid when
the standard deviation in life span is small compared with the
mean, as is the case for human red cells [15]. As discussed above,
our previous study [13] showed that for murine platelets the
standard deviation is actually quite significant (C.V. ,25%),
resulting in a significant ‘‘tail’’ to the population survival curve –
the curve tapers out after initially appearing linear. Therefore the
approximation of fixed natural life span is unlikely to be
appropriate for this system. The only way for the Dornhorst
model to fit to the tail region of the population survival curve is by
increasing the random loss fraction. Therefore, we wondered
whether the apparently high values for the random loss estimated
by the Dornhorst model were, in fact, an artefact of assuming a
fixed death time.
Dornhorst Lognormal-Senescent (DLS) model
To address the issue of artefactually high values of the random
loss fraction with the Dornhorst model, we developed a model,
which we refer to as the ‘‘Dornhorst Lognormal-Senescent’’ model
(or DLS model) see Materials and Methods, where senescent
death occurs according to a lognormal distribution, rather than at
a fixed time, and random death occurs independently – potentially
cutting short the natural life span. Thus the DLS model has three
parameters – the mean, m, and standard deviation, s, of the
lognormal distribution of senescent life spans, and the rate
constant for random loss of platelets, r (as well as the additional
parameter for the labeling efficiency, e1, needed to fit real data).
The random loss fraction, f, in this model depends on the
distribution of natural life spans, L(?), and the random loss rate
constant, r, via Equation (12) in Materials and Methods. The
choice of a lognormal distribution for natural lifespan is not
essential, and similar results can be obtained with other positive,
right-skewed distributions such as the gamma distribution.
Figure 3 illustrates the results of fitting the DLS model to the
population survival data across the three genotypes, and Table 3
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Figures 3B and C show the expected result of increasing mean life
span and standard deviation of life span across the genotypes, and
Figures S1C and D show that the result of increasing mean log life
span while standard deviation log lifespan remains constant (within
parameter constraints), seen in the LS model, is also true in the
DLS model. More importantly, as can be seen in Figure 3E, this
model does appear to allow for much lower value of the random
loss fraction when compared with the Dornhorst model, Figure 2E.
In Bcl-x+/Plt20 there is little evidence for random loss (best-fit
f = 0.00, 95% C.I. [0.00,0.39]), while in wild-type (best-fit f = 0.31,
95% C.I. [0.09,0.46]) and Bak2/2 (best-fit f = 0.34, 95% C.I.
[0.04,0.51]). Thus, while the best-fit value may still seem rather
high in wild-type and Bak2/2, the confidence intervals are very
wide and therefore it would be inappropriate to draw strong
conclusions regarding the value of this parameter and its biological
significance.
The DLS model can be viewed in two ways – (1) as an extension
of the LS model to include a random loss term, or (2) as an
extension of the Dornhorst model to allow a non-zero standard
deviation in the distribution of natural lifespan (the choice of
distribution is obviously not unique, but here we work with the
lognormal distribution). Either way, there is one extra parameter
in the more complex model (the DLS model) compared with the
simpler model (LS or Dornhorst) and the simpler model is said to
be ‘‘nested’’ in the more complex model. The F-test is a statistical
test that can be used in circumstances such as these (nested
models), to say whether the addition of extra parameters with the
more complex model is justified by the improvement in quality of
fit [18]. The test as it applies here is described in Materials and
Methods. The results of an F-test comparing the DLS to the LS
model are shown in Table 4, and comparing the DLS to the
Dornhorst model in Table 5. The F-test can be viewed as a type of
statistical hypothesis test, with the simpler model (LS or Dornhorst)
considered the null hypothesis, and the more complex model
(DLS) considered the alternate hypothesis. The relevant quantities
for each fit are the sum of square residuals (s.s.r.) and the number
of degrees of freedom (df), which is equal to the number of data
points minus the number of parameter values. The F-test shows
the improvements in quality of fit were statistical significant for
both model comparisons in the wild-type and Bak2/2 genotypes,
but not for either model comparison in the Bcl-x+/Plt20 genotype.
This improvement in quality of fit as assessed by the F-test could
be taken as evidence the DLS model is superior to either the LS or
Dornhorst models, at least in the wild-type and Bak2/2 genotypes.
However, this result must be interpreted with caution. As noted
above, the wide confidence intervals for the random loss
parameter limit the usefulness of the results. For example, no
firm conclusion can be drawn as to how the random loss fraction
varies, if at all, between the three genotypes studied here.
Fitting to the cohort survival data as well as the
population survival data does not substantially improve
confidence intervals
Tables S1, S2, S3 show the results of fitting each of the models –
the LS, Dornhorst, and DLS models – to both the population and
cohort survival data for each of the three genotypes. As discussed
above, to fit the cohort survival data necessitates the introduction
of two additional parameters – the labeling efficiency for the
second label, e2, and the biotin half-life, b1/2. As can be seen from
comparing the confidence intervals in these tables to those in
Tables 1, 2, 3, there is very little improvement (narrowing) of the
confidence intervals for the parameters, in particular the random
loss fraction, f, of most interest in this paper. Thus the cohort
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values. As an illustration of the fits that can be obtained to the
double-labeling data, Figure S2 shows fits using the DLS model for
each of the genotypes, with the corresponding best-fit parameter
values and 95% confidence intervals are reported in Table S3.
Tables S1 and S2 report the best-fit parameter values and 95%
confidence intervals for fits to the double-labelling data with the
LS and the Dornhorst models, respectively.
Comparison between mice and humans
Some quantitative comparisons between mice and humans are
insightful at this point. At steady-state production of platelets (S)
must balance their clearance/loss, therefore a rough estimate of
the production rate is the total platelet count (N) divided by the
mean life span of platelets (m), S<N/m. Typical values of these
quantities in humans are approximately N = 2506103/mL, m = 9
days, and so S<286103/mL/day. In wild-type C57BL/6 mice,
approximately N = 12006103/mL, m = 4 days, and so
S<3006103/mL/day. Therefore mice have a roughly 10-fold
higher production/turnover of platelets per microliter of blood per
day, compared with humans.
Furthermore, according to Equation (15) in Materials and
Methods, the random loss fraction equals the absolute random
loss rate divided by the production rate, f = R/S. The absolute
random loss rate is the random loss rate constant times by the
platelet count, R = rN, and is equivalent to Hanson et al.’s ‘‘fixed
requirement for platelets’’ [14]. Hanson et al. estimated the fixed
requirement for platelets in humans to be 76103/mL/day.
Combining this value with the estimate of the production rate
above, gives f<0.25, in reasonable agreement with what Hanson
et al. reported (f<0.18) given the approximate nature of these
calculations. The fixed requirement for platelets in mice is
currently unknown, however if it is the same as in humans,
Equation (15) would imply that the random loss fraction would
only be f<0.02, due largely to the much higher production rate in
mice.
Of course, these calculations are only estimates, however they
give some insight into the expected value of the random loss
fraction if the fixed requirement for platelets is the same between
mice and humans. For technical reasons discussed further below,
such a low value of the random loss fraction (f<0.02) would be
very difficult to detect in the survival curves. By contrast, the
higher values of the random loss fraction reported in Figure 3
(f<0.35) can be seen to correspond to a much higher fixed
requirement for platelets. Figure 4 shows the fixed requirement for
platelets, expressed per microliter of blood per day for ease of
comparison to Hanson et al.’s results. As can be seen, in wild-type
and Bak2/2 the fits would suggest a fixed requirement for platelets
of closer to 1006103/mL/day, whereas in Bcl-x+/Plt20 the fixed
requirement was not convincingly detectable.
Several resolutions are possible. Our results may be correct and
mice may indeed have a fixed requirement for platelets of around
1006103/mL/day, much higher than the equivalent figure in
humans of 76103/mL/day. The fact that we could not detect this
fixed requirement in the Bcl-x+/Plt20 genotype might be explained
by the fewer data points on those survival curves making it difficult
to detect the precise curvature. If the difference between species is
indeed real, consideration of other quantitative differences in
mouse versus human physiology (such as body weight, blood
volume, platelet size and surface area of vessels) may prove
insightful. Alternatively, our results are misleading due to technical
difficulties in extracting the value of the random loss fraction from
the survival curves. We therefore decided to explore some of the
technical difficulties associated with fitting the model to data, and
the implications for the interpretation of our results.
Trade-off between mean life span and random loss
fraction in the DLS model
The poor constraint on the random loss fraction revealed by the
Monte Carlo simulation warranted further investigation. Part of
the difficulty appears to stem from the fact that small values of the
random loss fraction have only very subtle effects on the predicted
survival curves. Figure 5A illustrates this point. Here we have
generated theoretical predictions for the population survival curve
with the DLS model by keeping the natural life span distribution
constant while the random loss fraction is varied. As long as the
random loss fraction is relatively small (say, 0.4 and below in the
figure) the survival curve takes a qualitatively very similar shape. It
looks linear initially, and tapers out to a tail around the mean
natural life span. It would be very difficult by eye to distinguish the
effect of the increasing the random loss fraction from shortening
Table 4. F-test to compare best fits with the LS model (the null hypothesis) versus the DLS model (one extra parameter – the
alternative hypothesis).
#data points #paramsnull dfnull #paramsalt dfalt ssrnull ssralt F P
Bcl-x+/Plt20 48 3 45 4 44 295.2 295.2 0.00 1
wild-type 60 3 57 4 56 106.7 95.2 6.77 0.011
Bak2/2 78 3 75 4 74 314.5 290.5 6.11 0.016
doi:10.1371/journal.pone.0057783.t004
Table 5. F-test to compare best fits with the Dornhorst model (the null hypothesis) versus the DLS model (one extra parameter –
the alternative hypothesis).
#data points #paramsnull dfnull #paramsalt dfalt ssrnull ssralt F P
Bcl-x+/Plt20 48 3 45 4 44 314.4 295.2 2.86 0.098
wild-type 60 3 57 4 56 140.2 95.2 26.5 3e-6
Bak2/2 78 3 75 4 74 335.2 290.5 11.37 0.0012
doi:10.1371/journal.pone.0057783.t005
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the mean natural life span. It is only when the random loss fraction
is relatively large (say, 0.6 and above in the figure) that the initial
segment of the survival curve starts to take a noticeably non-linear
shape due to the contribution of random loss. The trade-off
between the mean life span parameter and the random loss
fraction is further illustrated in Figure 5B, which is a scatter-plot of
mean life span versus random loss fraction for the wild-type
genotype from the Monte Carlo simulation. Linear regression was
performed and Pearson’s correlation co-efficient was calculated,
which showed a high correlation between these two parameter
values (r2 = 0.94). This result further illustrates the point that the
poor constraint on the random loss fraction is largely due to a
trade-off with the mean life span – namely, a small increase in both
simultaneously can produce an almost identical initial slope to the
population survival curve. For completeness, Figures 5C and D
show that there is much weaker correlation of the random loss
fraction with other parameters of the model – the standard
deviation in life span and the labeling efficiency. Similarly, Figure
S3 shows little pair-wise correlation amongst the other parameters
of the model.
Relationship between parameter constraint and
experimental uncertainty
Finally, we attempted to quantify the relationship between
experimental uncertainty and parameter constraint in this system.
In practice it is impossible to eliminate experimental uncertainly
entirely or to vary its degree. Therefore, to answer this question we
decided to fit to simulated data generated directly from the model
with varying degrees of random noise added. We chose to fix the
mean and standard deviation at m= 100 hr, s= 25 hr, and vary
the random loss fraction over a range of values, f = 0, 0.2, 0.4, 0.6,
and 0.8. For each value of f we generated baseline ‘‘ideal’’ data.
Experimental uncertainty was modelled as Gaussian noise with a
mean of 0 and a standard deviation of varying magnitude. For
each value of the noise we simulated a single data set and fit the
DLS model to it, followed by the Monte Carlo technique to
estimate confidence intervals, exactly as was done for the real data.
The resulting confidence intervals are shown in Figure 6, (A)
f = 0.2, (B) f = 0.8, representative of low and high random loss
fractions, respectively. For all values of f, as the value of the
random noise is increased the confidence intervals rapidly widen.
We note, however, that for higher values of f the confidence
intervals tend to be narrower for any given value of the noise. This
point is illustrated in Figure 6C which plots the interquartile range
as a function of f for different values of the noise. Roughly, at
f = 0.8 an equivalent interquartile range can be achieved with
twice as much noise compared with f = 0.2.
To be able to draw useful conclusions as to how the random loss
fraction varies between individuals or in different disease states,
one requires relatively narrow confidence intervals around the
parameter values. One can see from Figure 6 that reasonable
confidence intervals are only achieved at the lower values of the
random noise, say s.e.m. = 0.2% and below. In practice, the
implication is that the standard error in the mean (s.e.m.) of the
data points must be reduced below this threshold to achieve that
level of parameter constraint. Theoretically, this can be achieved
in two ways – (1) by reducing the experimental uncertainty, or (2)
increasing the number of replicates. Usually, the experimental
protocol will have been optimised and care taken to minimise as
much as possible all potential sources of experimental uncertainty.
Therefore, (1) will not usually be possible in practice. The
alternative, (2) is to increase the number of replicates. The s.e.m. is
related to the standard deviation of the data (s.d.) and the number





example, for our wild-type data, s.d. = 1.26%, n = 6, and therefore
s.e.m. = 0.56%. Assuming the s.d. cannot be improved, we would
need n.41 for s.e.m.,0.2%, and n.160 in order for s.e.m.,0.1%.
Thus the task of collecting sufficient experimental replicates is
clearly onerous and may be prohibitive in many circumstances.
However, as noted above, experimental uncertainty is somewhat
more tolerable at higher values of the random loss fraction; thus
the model is likely to find greater utility in disease states where
higher values of the random loss fraction might be expected.
Conclusions
Putting aside the issue of parameter constraint and differences
between mice and humans, our results are at least consistent with
the view that in steady-state the number of platelets is far in excess
of the body’s usual requirements and suggest an attractive
resolution to the debate over the relative importance of internal
and external processes in regulating platelet life span. Combined
with our previous results [13], we hypothesise that the default state
is for platelets to initiate apoptosis as they exhaust their natural life
span. This process is truly internal to the platelets and would occur
even if they were shielded from any form of environmental
damage. However, environmental factors, such as consumption in
blood clots or other forms of damage, lead to loss of some platelets
from the circulation before their natural life span is exhausted. The
proportion of platelets lost in this random way appears to be low in
healthy individuals, but is likely to be higher in disease states such
as certain thrombocytopenias or atherosclerosis, and with
advanced age, where survival curves look more curvilinear [19–
21].
Finally, we note that the model introduced here can be used to
study any cell population where there are two alternate fates – age-
dependent clearance according to a defined probability distribu-
tion (e.g. intrinsic senescent death), and random loss (e.g. due to
some extrinsic process that consumes or destroys cells indiscrim-
inately). This paradigm of competing intrinsic and extrinsic effects
on cell fate is found broadly in cell biology in vivo, thus our model
may prove useful in the analysis of other cell systems where
quantification of these two alternate fates is desired.
Figure 4. Values of absolute random loss rate (fixed require-
ment for platelets), extracted from the same fits of the DLS
model to survival data as illustrated in Figure 3. 1000 Monte
Carlo simulations were performed and fit to obtain parameters – box-
and-whisker plots indicate median, interquartile range, 2.5 and 97.5
percentiles, and outliers are plotted as individual dots.
doi:10.1371/journal.pone.0057783.g004
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Figure 5. Illustration of the difficulty in constraining the value of the random loss fraction using the Dornhorst-Lognormal-
Senescent model. (A) Theoretical population survival curves from the DLS model as the mean and standard deviation of natural life span are kept
constant (m = 100 hr, s = 25 hr) while the random loss fraction, f, is varied. Small values of the random loss fraction produce subtle changes in the
shape of the population survival curve. (B) Strong correlation between values of the random loss fraction (f) and the mean natural life span (m) in the
Monte Carlo simulation – r2 is the square of Pearson’s correlation coefficient; Slope is the gradient of the linear regression with 95% confidence
intervals in brackets [,]. The correlation with other parameters of the model is much less – (B) random loss fraction (f) versus standard deviation
natural life span (s), and (C) random loss fraction (f) versus labeling efficiency (e1).
doi:10.1371/journal.pone.0057783.g005
Figure 6. The effect of experimental uncertainty on the ability to constrain the value of the random loss fraction. Fits to simulated
data with Gaussian random noise of varying standard error of the mean (s.e.m.) added to simulate experimental uncertainty. (A)–(E) Simulated model
parameters: m = 100 hr, s = 25 hr, with (A) f = 0.2, (B) f = 0.8. For each value of f and each value of the s.e.m. of the noise, the fit was repeated 1000
times with independently-generated noise – the box-and-whisker plots indicate median, interquartile range, 2.5 and 97.5 percentiles, and outliers are
plotted as individual dots. (C) Interquartile range as a function of random loss fraction for the various levels of noise added to the simulated data. For
a given value of the s.e.m. of the noise, higher values of the random loss fraction are generally better constrained than lower (non-zero) values.
doi:10.1371/journal.pone.0057783.g006
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Materials and Methods
Ethics statement
All animal experiments complied with the regulatory standards
of, and were approved by, the Walter and Eliza Hall Institute
Animal Ethics Committee.
Mice
Mice with the Plt20 mutation in Bcl-x [12] and Bak2/2 mice
[22] have been previously described. Both mutations had been
backcrossed at least 10 generations to C57BL/6 background.
Wild-type controls were C57BL/6.
Experimental techniques
The experimental techniques for in vivo double labeling with
DyLight488 conjugated NHS-biotin and subsequent flow-cyto-
metric analysis to obtain population and cohort survival, have
been described previously [13]. Double labeling was performed in
6 mice of each genotype: Bcl-x+/Plt20, wild-type and Bak2/2.
Mathematical modeling
Mathematical modeling of a cell population in steady-state
where the distribution of life spans is fixed and known, has been
described previously [13,15,23]. We briefly review the main points
here to establish notation as a basis for discussing the Dornhorst
and DLS models. Let L(l) be the age-dependent distribution of life





At steady-state, the number of platelets of age a must be
proportional to the probability of surviving to that age. Therefore,











lL(l)dl is the mean life span. Because this is a
steady-state condition, after time t those platelets of age less than t





When fitting to population survival data, this theoretical survival
curve must be scaled by the efficiency of labeling with the first
label, e1 (typically approximately 0.9 for the X488 label in our
experiments), which is an additional parameter in the fitting.
Finally, assuming the total blood volume is constant, and platelet
production occurs at a constant rate, S, then the number of
platelets, N, is predicted to be:
N~Sm: ð4Þ
Platelet counts and all rates (of production and destruction) are
measured per microliter of total blood throughout this paper.
Lognormal-senescent (LS) model











The parameters m and s are the mean and standard deviation,
respectively, of the logarithm of life span. When the life span
distribution is lognormal, the survival curve always has an analytic
form [17].
Dornhorst model
The Dornhorst model was original developed to interpret red
cell survival curves [15]. Briefly, cells (in this case platelets) are
assumed to die at a fixed time, T, (senescent death) if they are not
earlier removed by random loss, which occurs at a constant rate, r.











The proportion of platelets that eventually are randomly lost
before they die of senescence (the ‘‘random loss fraction’’, f) is:
f ~1{exp({rT): ð8Þ






Here, we derive a model that combines both age-dependent
senescent death according to some distribution and age-indepen-
dent random death at a constant rate, r. This can be considered a
generalisation of the Dornhorst model where senescent death does
not have to occur strictly at some fixed time (T) but is distributed.
Following the same logic as above, the probability of surviving







In steady-state, the probability density of cell age in the population














, where f is the random loss fraction:
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The survival curve can then be calculated as above, Equation (3).
The steady-state platelet number can be derived by requiring
that the number of platelets dying at any instant balances the
production rate. If N is the total number of platelets in the








L(l)dl) is the rate of natural death at
age a, given life span distribution L(?). Equating this expression














As expected, when rR0 this equation reduces to Equation (4) for
the case of no destruction (f/rRm), and when L(l)?d(l{T) (a
delta function representing a fixed life span, T) it reduces to
Equation (7) for the Dornhorst model.





Where we have defined the instantaneous absolute total random
loss rate (R) as the random loss rate constant (r) times by the
platelet count (N). Thus, the random loss fraction is equal to the
ratio of absolute total random loss rate (R) to the production rate
(S). It follows that in situations where random loss is predominantly
due to hemostatic consumption, the random loss fraction is a
measure of the balance between the requirement for platelets (R)
and their production (S).
When the natural life span distribution is chosen to be
lognormal, we refer to this model as the Dornhorst Lognormal-
Senescent (DLS) model. When the standard deviation in life span
approaches zero, it reduces to the classic Dornhorst model.
Calculation of predicted cohort label
The double-labeling procedure involves injecting a second label
after a delay of time, d (24 hrs in our experiments), in order to
establish a ‘‘cohort’’, negative for the first label but positive for the
second, that were born within the intervening time. In our
experiments the second label is biotin, which is less effective than
X488 in labeling platelets (the labeling efficiency, e2, is approx-
imately 0.6). Ideally, the distribution of ages in the cohort at the






However, in practice we need to account for the labeling













{ rzL(a)ð Þpcohort(a,t), ð18Þ
with Equation (16) as the initial condition and with the boundary
conditions:
pcohort(a~0,t)~e2Se
{ log (2)(t{d)=b1=2 ,
pcohort(a??,t)?0:
ð19Þ
Here, the biotin half-life, b1/2, has been used to account for the
additional labeling of some newly-produced platelets, as described
previously [13]. The area under pcohort(a,t) represents the relative






Best fits to survival data were generated by minimizing the sum
of square residuals between the data and model predictions using
custom code written in MATLAB, as described previously [13],
based on the MATLAB function fmincon using the ‘interior point’
algorithm. For numerical integration to obtain population and
cohort survival curves, the number of grid points was chosen to be
1000. The range for integration was [0,exp(m+4s)] for the LS or
DLS model (where m and s are the mean and standard deviation of
the log of lifespan),or [0,T] for the Dornhorst model. To overcome
the problem that the best fit may depend on the starting model
parameters, we adopted a technique of finding the best fit multiple
times from different starting points. Parameter starting points were
chosen uniformly and randomly from an interval, and the fit was
repeated to see if an improvement to the previous best could be
found. Once a better fit had not been found for the previous 100
starting points (population fits) or 10 starting points (population
and cohort fits), the optimization was terminated.
The Monte Carlo technique for estimating confidence intervals
is slightly different to the bootstrapping technique used in our
previous study [13], therefore we describe it here briefly. The
method is described in [18]. First a best fit to the data is generated.
Next, the experimental error about the model fit is modeled as








where ssr is the sum of square residuals of the best fit, and df is the
number of degrees of freedom of the data, which is equal to the
number of data points minus the number of model parameters.
Simulated data is then generated by adding Gaussian noise of this
magnitude to each data point on the curve. Since there were 6
replicates in the original experiment we simulate 6 survival curves
for each Monte Carlo iteration. A new best fit is then calculated as
above. This procedure was repeated for 1000 iterations, thus
producing an empirical distribution of parameter values that one
might expect to find from repetitions of the experiment. These
numerical distributions are used to create the box-and-whisker
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plots and correlations between parameters in the figures of this
paper, and the 95% confidence intervals reported in tables.
F-test
In general, a more complicated model (one with more
parameters) should be expected to produce an improvement in
the quality of fit to data (as measured by the sum of square
residuals) compared with a simpler model. The F-test [18,24] can
be used to assess the statistical significance of the improvement in





where ssrnull and ssralt are the sum of square residuals and dfnull and
dfalt are the number of degrees of freedom (the number of data
points minus the number of model parameters) for the simpler
(null hypothesis) and more complicated (alternate hypothesis)
models, respectively. Under the null hypothesis that any improve-
ment in fit is due to chance alone, a theoretical distribution of the
F statistic (depending on the number of degrees of freedom of the
two models) can be calculated. Thus, a p-value can be derived that
can be interpreted as the likelihood, by chance alone, that the F
statistic takes a value at least as large as is observed. We adopted
the conventional threshold value of p = 0.05 for statistical
significance. Roughly speaking, if the relative improvement in
the sum of square residuals is much greater than the relative
increase in the number of degrees of freedom, then the result is
likely to achieve statistical significance.
The F-test is only valid when the simpler model is a special case
of the more complicated model (i.e. the models are nested). In this
paper, the classic Dornhorst model and the LS model are both
special cases of the DLS model – the Dornhorst model
corresponds to the standard deviation of life span being fixed to
be zero, and the LS model corresponds to the random loss rate
constant being fixed to zero. Therefore, the F-test can be used to
assess whether the improvement in the quality of fit with the DLS
compared with either the Dornhorst or LS models justifies the
inclusion of the extra parameter.
Supporting Information
Figure S1 Log-transformed parameters of the Lognormal-
Senescent and Dornhorst-Lognormal-Senescent model fits. (A)
and (B) Lognormal-Senescent model mean log life span (m) and
standard deviation log life span (s), respectively. (C) and (D)
Dornhorst Lognormal-Senescent model mean log life span (m) and
standard deviation log life span (s), respectively. It is primarily the
mean log life span rather than the standard deviation log life span
that varies between the genotypes in either model. The three
genotypes are identified by colour – Bcl-x+/Plt20 (blue), wild-type
(green) and Bak2/2 (red).
(EPS)
Figure S2 Fits of the Dornhorst Lognormal-Senescent model to
both population and cohort survival data for the different
genotypes. (A) Bcl-x+/Plt20. (B) wild-type. (C) Bak2/2.
(EPS)
Figure S3 Weak correlation amongst the parameters of the DLS
model other than the random loss fraction. Linear regression of
the Monte Carlo parameters for the wild-type genotype – r2 is the
square of Pearson’s correlation coefficient; Slope is the gradient of
the linear regression with 95% confidence intervals in brackets [,].
(A) mean natural life span (m) versus standard deviation natural life
span (s). (B) labeling efficiency (e1) versus mean natural life span
(m). (C) labeling efficiency (e1) versus standard deviation natural life
span (s).
(EPS)
Table S1 Best-fit LS model parameters from fits to population
and cohort survival data for each genotype, with 95% C.I.’s from
the Monte Carlo technique in brackets.
(PDF)
Table S2 Best-fit Dornhorst model parameters from fits to
population and cohort survival data for each genotype, with 95%
C.I.’s from the Monte Carlo technique in brackets.
(PDF)
Table S3 Best-fit DLS model parameters from fits to population
and cohort survival data for each genotype, with 95% C.I.’s from
the Monte Carlo technique in brackets.
(PDF)
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